Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Pharmaceutical Technology on MSN

Denali makes $275M funding agreement with Royalty Pharma

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
Fierce Biotech

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment

Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.
TipRanks on MSN

Denali Therapeutics secures $275M royalty funding deal

Denali Therapeutics ( ($DNLI) ) has issued an update. On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty ...

Denali: Regulatory Delay Is A Strategic Opportunity

Denali's validated platform, strategic pipeline, and experienced management present a compelling long-term investment opportunity. Find out why DNLI stock is a Buy.
Good News Network

Boy with Rare Genetic Disorder Amazes Doctors After World-First Gene Therapy

The first child in history has successfully been treated with a new genetic therapy for an ultra-rare developmental defect ...
Smithsonian Magazine

This Toddler Was the First Person to Receive a Test Treatment for a Rare Genetic Disorder. Nine Months Later, His Progress Is Inspiring Hope

Oliver Chu is one of five kids participating in a clinical trial investigating a gene therapy for Hunter syndrome, a disorder with symptoms akin to childhood dementia that limits life expectancy ...
The Reporter

Westfield Welcome makes Wesley’s wish come true!

Mayor Willis and many city staff members participated in a parade for Wesley, a four-year-old resident with Hunter Syndrome ...

3-Year-Old Boy with Rare Condition Amazes Doctors by Becoming World's First Gene Therapy Patient

Oliver Chu was born with a rare genetic condition called Hunter syndrome that impacts physical and mental development. The ...